Clinical Trial

Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants

Study acronym: GUT-LUNG RSV
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young children, and a substantial proportion of severe cases occur in previously healthy infants. The gut-lung axis suggests that gut microbiome composition may modulate respiratory immune responses. This prospective observational study in Vietnam will compare gut microbiome profiles and systemic immune cytokine responses between infants with severe RSV infection and those with mild RSV infection, aiming to identify microbiome-immune signatures associated with disease severity.
Trial Details
NCT Number NCT07417657
Lead Sponsor Phuc Huu Phan
Conditions Respiratory Syncytial Virus Infection, Bronchiolitis, Viral Lower Respiratory Tract Infection (LRTI)
Enrollment 250 participants
Start Date 2026-04-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-18